Clinical Trials Browser

INDUSTRY × Bites and Stings × blinatumomab × Clear all

NCT06063317 2026-03-06

OASIS

Phase 1 Terminated

Bites and Stings

NCT00274742 2015-01-16

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Phase 1 Completed

76 enrolled 15 charts

Bites and Stings, Lymphoma, Non-Hodgkin, Recurrence